ReadeRx Therapeutics

RNA-based Cancer Therapeutics

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in January 2023, ReadeRx Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer treatments.

Business overview

ReadeRx Therapeutics is a Health Tech & Life Sciences company specializing in RNA-based cancer therapeutics. The company develops small molecule inhibitors that target the RNA binding protein IGF2BP1, which plays a pivotal role in stabilizing pro-oncogenic RNAs in various cancer types. By inhibiting IGF2BP1, ReadeRx aims to offer a novel treatment strategy for cancer, serving the pharmaceutical and healthcare industries.

Log in to access full profile

Company Intelligence Q&A

What is ReadeRx Therapeutics' primary focus?
ReadeRx Therapeutics is focused on developing RNA-based cancer therapeutics, specifically targeting the RNA binding protein IGF2BP1 with small molecule inhibitors.
When was ReadeRx Therapeutics founded?
ReadeRx Therapeutics was founded in January 2023.
What is the current employee size of ReadeRx Therapeutics?
ReadeRx Therapeutics currently has 1–10 employees.
What is the strategic importance of IGF2BP1 in cancer therapy?
IGF2BP1 is an oncofetal RNA binding protein that is widely expressed during development but significantly reduced in normal mature tissues. In many cancers, it is reactivated and plays a crucial role in stabilizing pro-oncogenic RNAs, promoting tumor growth. Inhibiting IGF2BP1 is therefore considered a highly promising strategy for cancer therapy.
What stage is ReadeRx Therapeutics currently in?
ReadeRx Therapeutics is currently in the Pre-Funding stage, with its product in the R&D phase.
Log in to access full profile